Pazdurcanumab: US FDA’s Top Cancer Official Weighs In On That Big Neurology Approval

Richard Pazdur is eager for a conversation about how to improve the Accelerated Approval pathway. The OCE director welcomes aducanumab’s approval – both on its own terms but also as an opportunity to broaden the discussion.